Construction method of tumor microenvironment scoring system for predicting gastric cancer immunotherapy and molecular probe

Abstract

The invention provides a group of molecular probes for detecting and evaluating a gene set of a tumor microenvironment. The molecular probes comprise 44 nucleotide sequences as shown in SEQ ID NO: 1-44. A screened probe is used for carrying out NanoString digital expression detection on the expression of a target gene in a same hole, a digital gene expression profile is drawn, and the probe can be used for evaluating the immunotherapy effect. The invention further provides a construction method of a multi-gene scoring model for evaluating the gastric cancer tumor microenvironment, and 44 gene sets capable of representing different microenvironment types are screened out and can be used for establishing the tumor microenvironment multi-gene scoring model for evaluating patients. By effectively evaluating the tumor microenvironment, the model not only can be used as a good prognosis biomarker, but also can predict checkpoint inhibitor immunotherapy response of various tumors, and has important significance and clinical application value for realizing individualized medical treatment and saving medical resources at the same time.

Description

technical field [0001] The invention belongs to the field of biological information, and relates to a gene set for evaluating tumor microenvironment, a method for constructing a scoring system, and a molecular probe for detecting the expression level of each gene in the gene set. Background technique [0002] Gastric cancer is a malignant tumor with a high incidence among Chinese residents. According to the data of GLOBOCAN in 2012, the new cases of gastric cancer in China accounted for 42.5% of the global total, and the number of deaths accounted for 45% of the world. The prognosis of patients with advanced gastric cancer is poor, the incidence of recurrence or disease progression after first-line chemotherapy is high, the survival rate of patients is low, and the options for later-line treatment are limited. The biggest challenge of immunotherapy is that only some patients can benefit from it. How to accurately screen out the patient group that can benefit from checkpoint ...

AI Technical Summary

Problems solved by technology

This phase III clinical randomized controlled study showed that the expression level of PD-L1 has limitations: ①The expression of PD-L1 in tumors is heterogeneous, different tumor types and different regions of the same tumor, the difference between tumor lesions and metastases There may be differences in the expression of PD-L1 between patients; ②The lack of standardization of antibodies and staining, the expression level of PD-L1 is mainly evaluated by immunohistochemical staining

[0006] In summary, at present, the stability of various biomarkers in predicting the efficacy of PD-1 / PD-L1 monoclonal antibodies is not good, and they are all concentrated in the tumor cells themselves, which has certain limitations and ignores the tumor survival environment, both tumor microbiology and The evaluation of environmental conditions is not comprehensive in terms of the mechanism of action of immunotherapy, which partly explains the low response rate of gastric cancer to checkpoint inhibitors in clinical trials of multiple biomarkers; therefore, more accurate Biomarkers for predicting efficacy of immune checkpoint inhibitor PD-1 / PD-L1 monoclonal antibody

Images